Year: 2024
Type: article
Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
Authors: Potter, Huntington, Arendash, Gary W., Bennett, Steven, Boyd, Timothy
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Keywords: cognitive impairment, neuroinflammation, inflammatory mediators, Flt3 ligand, interleukin-6, macrophage migration inhibitory factor, erythropoietin, VEGF-A, hypoxia-inducible factor-1α, insulin-like growth factor I, TNF-α, granulocyte colony-stimulating factor, GM-CSF, macrophage colony-stimulating factor, stem cell factor, darbepoetin alfa, metalloproteinases, neuroprotection, cognitive enhancement
Open Access status: green
OpenAlex ID: W7030158902
